MYC and breast carcinoma: Another recently identified small compound, MYCMI-6, also inhibits c-MYC-MAX heterodimerisation by binding to the bHLH-LZ domain of c-MYC and abolishing c-MYC-mediated transcription in breast cancer cells [107].